학술논문
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024
Document Type
Article
Author
Moline, H.L.; Tannis, A.; Toepfer, A.P.; Goldstein, L.; McKeever, E.R.; Kalman, C.; Clopper, B.R.; McMorrow, M.L.; Dawood, F.S.; Williams, J.V.; Michaels, M.G.; Musa, S.; Boom, J.A.; Sahni, L.C.; Piedra, P.A.; Englund, J.A.; Klein, E.J.; Zerr, D.M.; Halasa, N.B.; Stewart, L.S.; Betters, K.A.; Staat, M.A.; Schlaudecker, E.P.; Rohlfs, C.; Weinberg, G.A.; Szilagyi, P.G.; Albertin, C.; Selvarangan, R.; Schuster, J.E.; Banerjee, D.; Link-Gelles, R.; Payne, A.; Wiegand, R.; Correa, X.A.; Pulido, C.G.; Grioni, H.; Strelitz, B.; Avadhanula, V.; Munoz, F.M.; Fregoe, W.; Peri, S.; Sasidharan, A.; Johnson, M.; Dauer, K.
Source
In: Morbidity and Mortality Weekly Report . (Morbidity and Mortality Weekly Report, 7 March 2024, 73(9):209-214)
Subject
Language
English
ISSN
1545861X
01492195
01492195